PARAMUS, N.J., Jan. 8, 2013 /PRNewswire/ -- Proteonomix, Inc.
(the "Company")(Symbol PROT), a biotechnology company (the
"Company") focused on developing therapeutics based upon the use of
human cells and their derivatives, announced today that the
University of Medicine & Dentistry of New
Jersey (UMDNJ) in conjunction with the Company has commenced
enrollment of patients with End Stage Liver Disease (ESLD) in its
clinical trial of UMK-121.
Michael Cohen, President and CEO
of the Company, stated; "We have began to screen new patients for
the UMK-121 trial and have enrolled our first candidate into the
trial. We expect to enroll more patients in the upcoming months.
The treatment of our first patient on the UMK-121 trial is a major
step forward for the company and demonstrates the company's ability
to move new therapies into therapeutic testing. Two additional
trials of UMK-121 are presently being developed in cancer and heart
disease which we intend to initiate in 2013."
About Proteonomix, Inc.
Proteonomix is a biotechnology company focused on developing
therapeutics based upon the use of human cells and their
derivatives. The Proteonomix family of companies includes
Proteoderm, StromaCel, PRTMI and THOR Biopharma. Proteoderm is a
wholly owned subsidiary that has developed an anti-aging line of
skin care products. StromaCel develops therapeutic modalities for
the treatment of cardiovascular disease and for treatment of
patients who have suffered post-myocardial infarction. Proteonomix
Regenerative Translational Medicine Institute, Inc. (PRTMI) intends
to focus on the translation of promising research in stem cell
biology and cellular therapy to clinical applications of
regenerative medicine. Additional information is available at
www.proteonomix.com and www.proteoderm.com.
Forward-looking statements:
Certain statements contained herein are "forward-looking
statements" (as defined in the Private Securities Litigation Reform
Act of 1995). Proteonomix, Inc. cautions that statements made in
this press release constitute forward-looking statements and makes
no guarantee of future performance. Actual results or developments
may differ materially from projections. Forward-looking statements
are based on estimates and opinions of management at the time
statements are made.
SOURCE Proteonomix, Inc.
